Wigen Biomedicine Technology (Shanghai)

Wigen Biomedicine Technology (Shanghai), based in Shanghai, China, is a biotechnology company. Wigen Biomedicine develops innovative anti-tumour drugs using small-molecule covalent/allosteric, PROTAC and drug-conjugate technology platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing WJB001. The largest, NCT05773820 (A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumours), plans to enrol 210 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.